Proven DNBSEQ™ sequencing technology combines the power of DNA Nanoballs (DNB™), PCR-free Rolling Circle Replication, Patterned Nano Arrays and cPAS to deliver a new level of data clarity and affordability.

Learn About DNBSEQ™ Technology

BGI provides high quality, affordable sequencing services and NGS solutions for DNA Research & RNA research applications, multi-omics solutions and more.

Human Whole Genome Sequencing

Exome Sequencing

De Novo Sequencing

Plant/Animal Whole Genome Sequencing

RNA Sequencing

Small RNA Sequencing

16s/18s/ITS Sequencing

Metagenomic Sequencing

Single Cell Sequencing

Our Mission is Simple: to provide researchers and healthcare professionals with the highest quality multi-omics data, at rapid turnaround times, with the best possible scientific support, all at industry leading pricing. Access some of our popular sequencing services and genomics solutions below.

BGI - high quality, affordable sequencing services and NGS solutions.1

• Over 20 years of genomics expertise 
• Comprehensive multi-omics service portfolio
• Cutting edge NGS and mass spec platforms
• Local lab solution with rapid turnaround 

Premium Omics Services at Competitive Prices

<p>[av_layerslider id='39']

[av_three_fifth first]

[av_textblock size='' font_color='' color='']
</p><h1><span style="color: #034694;">Whole Genome Sequencing on the Revolocity™ System</span></h1>The Revolocity™&nbsp;system is the first fully automated, integrated high-capacity sequencing system for whole genome sequencing (WGS) applications.

At BGI, we know that not every partner needs to acquire this population-scale sequencing system. We’re therefore proud to announce our whole genome sequencing services on the Revolocity™ platform, providing you with affordable access to high quality whole genomes at 50X mean coverage.

- 50X genome
- High quality SNP, CNV, Indel and SV data
- Sequencing at our California facility
- Standard file formats
- Comprehensive bioinformatics included
<h1><span style="color: #034694;">Contact Us Now with Your Project Requirements or For More Information!</span></h1>
<a href="http://www.bgi.com/about-us/introduction-int/">Learn more about BGI</a>.
[/av_textblock]

[/av_three_fifth][av_two_fifth]
[av_textblock size='' font_color='' color='']
<h2 style="color: #003a8f; margin-bottom: -10px;">Contact Us For More Information!</h2>
[/av_textblock]

[av_contact email='matt.poulter@gmail.com, dsiu@completegenomics.com, matt.poulter@genomics.cn, gaoqiang@genomics.cn' title='' button='Submit' on_send='' sent='Thank you, your message has been sent. We will contact you shortly.' link='manually,http://' subject='BGI WGS Revolocity info request' autorespond='' captcha='' color='']
[av_contact_field label='Name' type='text' check='is_empty' options='' multi_select='' width=''][/av_contact_field]
[av_contact_field label='Company' type='text' options='' check='is_empty' width='' multi_select=''][/av_contact_field]
[av_contact_field label='Location' type='text' options='' check='is_empty' width='' multi_select=''][/av_contact_field]
[av_contact_field label='E-Mail' type='text' check='is_email' options='' multi_select='' width=''][/av_contact_field]
[av_contact_field label='Telephone Number' type='text' options='' check='' width='' multi_select=''][/av_contact_field]
[av_contact_field label='Message' type='textarea' check='is_empty' options='' multi_select='' width=''][/av_contact_field]
[/av_contact]
[/av_two_fifth]

Whole Genome Sequencing on the Revolocity™ Platform

<header><br/><h1 class="c-news__title"></h1><br/></header><br/><div class="entry-content"><br/><br/><br/><br/><br/><br/><br/><br/><br/><br/><table border="0" width="100%" cellspacing="1" cellpadding="3"><tbody><tr class="ccbnBgTtl"><td valign="top"><br/><h3><strong>Natera and BGI Genomics Announce Partnership to Commercialize Signatera Oncology Test in China and to Develop Reproductive Health Tests in Select Markets on BGI’s DNBseq™ Technology Platform</strong></h3><br/></td></tr><tr class="ccbnBgTxt"><td valign="top">&nbsp;<br/><div class="xn-content"><br/><br/><strong>Partnership marks significant milestone for Natera in monetizing its Signatera MRD test and for BGI Genomics a strong endorsement of its DNBseq™ technology platform by a leader in cell-free DNA genetic testing</strong><br/><br/>SAN CARLOS, Calif.&nbsp;and&nbsp;SHENZHEN, China,&nbsp;March 11, 2019&nbsp;/PRNewswire/ —&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=2398906-1&amp;h=2489610013&amp;u=http%3A%2F%2Fwww.natera.com%2F&amp;a=Natera%2C+Inc." target="_blank" rel="nofollow noopener">Natera, Inc.</a>&nbsp;(NASDAQ: NTRA), a global leader in cell-free DNA genetic testing, and&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=2398906-1&amp;h=4138450103&amp;u=https%3A%2F%2Fwww.bgi.com%2Fus%2F&amp;a=BGI+Genomics+Co.%2C+Ltd.%2C" target="_blank" rel="nofollow noopener">BGI Genomics Co., Ltd.,</a>&nbsp;(300676.SZ), the largest cell-free DNA clinical testing laboratory in&nbsp;China&nbsp;and one of the world’s leading genomics companies, today announced a&nbsp;$50 million&nbsp;partnership to commercialize&nbsp;Natera’s&nbsp;Signatera™ MRD test in&nbsp;China, and to develop reproductive health tests in select markets on BGI’s sequencing instruments using the DNBseq™ NGS technology platform.<br/><br/>The Natera Signatera MRD and molecular monitoring test will be offered in&nbsp;China, first through specialty hospital networks and then more broadly, once&nbsp;Natera&nbsp;and&nbsp;BGI Genomics&nbsp;gain&nbsp;China’s&nbsp;regulatory approval for use of the Signatera test on the DNBseq™ technology platform. DNBseq™ is the market name of BGI’s proprietary sequencing technology, which supports its portfolio of next-generation sequencing platforms.&nbsp;BGI Genomics’&nbsp;genetic testing leadership position in&nbsp;China, where it performs over 1 million cell-free DNA tests annually,1&nbsp;will accelerate&nbsp;Natera’s&nbsp;entry into this large and growing oncology market.<br/><br/>Cancer is the leading cause of death in&nbsp;China&nbsp;with roughly 4.3 million new cancer cases and 2.8 million deaths reported annually.2&nbsp;The molecular diagnostics market in&nbsp;China&nbsp;is a rapidly growing multi-billion-dollar market, driven largely by the rising incidence of cancer and infectious diseases.3<br/><br/>“Natera&nbsp;shares our core vision of improving human health by offering innovative genetic testing solutions that allow for earlier and more effective diagnosis of disease,” said&nbsp;Yin Ye, CEO at&nbsp;BGI Genomics. “Natera’s&nbsp;decision to launch its Signatera test into&nbsp;China&nbsp;on BGI’s DNBseq™ technology platform is a testament to both the quality and versatility of our technology. We look forward to working together with&nbsp;Natera&nbsp;for the general benefit of people&nbsp;worldwide and to expanding access to the DNBseq™ technology platform to other customers globally.”<br/><br/>“We are very impressed with BGI’s pace of innovation, its people, and its scale of operations in&nbsp;China,” said&nbsp;Steve Chapman, CEO at&nbsp;Natera. “BGI is a recognized world leader in next-generation sequencing and, we believe, the most qualified laboratory partner for us in&nbsp;China. This deal continues&nbsp;Natera’s&nbsp;commercialization success in oncology, augmenting over 30 pharmaceutical trials currently underway, and is a strong endorsement of&nbsp;Natera’s&nbsp;leading technology in oncology and reproductive health.”<br/><br/>“We are excited for the opportunity to partner with an innovative leader like BGI to commercialize Signatera in&nbsp;China&nbsp;and expand the reach of&nbsp;Natera’s&nbsp;reproductive health technology in select markets, and we believe BGI has the capability to substantially reduce costs for offering our technology,” said&nbsp;John Fesko, Sr.&nbsp;Vice President of Business Development at&nbsp;Natera. “This deal complements our strategic partnerships with existing sequencing providers and does not alter our plans with them. This exciting alliance is key to our vision of being the application layer for genetic testing worldwide.”<br/><br/>About BGI<br/><a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=2398906-1&amp;h=3949147033&amp;u=https%3A%2F%2Fwww.bgi.com%2Fus%2F&amp;a=BGI" target="_blank" rel="nofollow noopener">BGI</a>&nbsp;was founded in 1999 with the vision of using genomics to benefit mankind and has since become one of the largest genomics organizations in the world. With a focus on research and applications in the healthcare, pharmaceutical, conservation and environmental fields, BGI has a proven track record of innovative, high-profile research that has generated over 1,600 publications.&nbsp;BGI Genomics&nbsp;is an independent division of&nbsp;BGI Group, and was listed on the&nbsp;Shenzhen Chi-Next exchange in&nbsp;July 2017.&nbsp;BGI Genomics’&nbsp;goal is to make state-of-the-art genomics highly accessible to the global research community and clinical markets by integrating the industry’s broadest array of leading technologies, including BGI’s own DNBseq™ technology platforms, economies of scale, and expert bioinformatics resources.&nbsp;BGI Genomicsalso offers a wide portfolio of transformative genetic testing products across major diseases, enabling medical providers and patients worldwide to realize the promise of genomics-based diagnostics and personalized healthcare. Follow&nbsp;BGI Genomics&nbsp;on&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=2398906-1&amp;h=2839640756&amp;u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fbgi-shenzhen%2F%3FviewAsMember%3Dtrue&amp;a=LinkedIn" target="_blank" rel="nofollow noopener">LinkedIn</a>&nbsp;and&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=2398906-1&amp;h=1067828996&amp;u=https%3A%2F%2Ftwitter.com%2FBGI_Genomics&amp;a=Twitter" target="_blank" rel="nofollow noopener">Twitter</a><u>.</u><br/><br/>About&nbsp;DNBseq™&nbsp;Technology<br/><a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=2398906-1&amp;h=2184750478&amp;u=https%3A%2F%2Fwww.bgi.com%2Fus%2Fdnbseq-ngs-technology%2F&amp;a=DNBseq%E2%84%A2%C2%A0" target="_blank" rel="nofollow noopener">DNBseq™&nbsp;</a>technology is a proprietary sequencing technology originally developed by MGI.<br/><br/>DNBseq™ sequencing technology is powered by PCR-free Rolling Circle Replication, combinatorial Probe-Anchor Synthesis (cPAS) and DNA Nanoballs (DNB) technology. The cPAS chemistry works by linking a fluorescent probe to a DNA anchor on the DNB, followed by high-resolution digital imaging. This combination of linear amplification and DNB technology reduces the error rate while enhancing the signal. In addition, the size of the DNB is controlled in such a way that only one DNB is bound per active site in the flow cell. This patterned array technology not only provides sequencing accuracy, but it also increases the chip utilization and sample density. Unlike PCR amplification, amplification errors arising from Rolling Circle Amplification do not accumulate exponentially, allowing DNBseq™ platforms to deliver a high level of data clarity.<br/><br/>NGS data from DNBseq™ technology is documented by a growing body of studies, with over 100 peer-reviewed publications to date. BGI has also published pilot data from its sequencing platforms running on DNBseq™ technology, including samples processed for human whole genome sequencing from the&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=2398906-1&amp;h=2012495783&amp;u=https%3A%2F%2Fbiobank.ctsu.ox.ac.uk%2Fcrystal%2Frefer.cgi%3Fid%3D657&amp;a=UK+Biobank" target="_blank" rel="nofollow noopener">UK Biobank</a>&nbsp;as part of a proof of concept study.<br/><br/>About Signatera™<br/><a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=2398906-1&amp;h=2460634685&amp;u=https%3A%2F%2Fwww.natera.com%2Fsignatera%2Fdifference&amp;a=Signatera" target="_blank" rel="nofollow noopener">Signatera</a>&nbsp;is the first circulating tumor DNA (ctDNA) test custom-built for molecular treatment monitoring and molecular residual disease (MRD) assessment. The test is available for research use only until its clinical launch planned for Q2 2019. The Signatera methodology differs from currently available liquid biopsy tests, which test for a fixed panel of therapeutically relevant genes. Signatera provides each individual with a customized blood test tailored to match the clonal mutations found in that individual’s tumor tissue. This maximizes accuracy for detecting the presence or absence of MRD in a blood sample, even at levels down to a single mutant molecule in a tube of blood. Signatera RUO also allows researchers to track additional mutations of interest, up to several hundred mutations, for clinical studies.<br/><br/>The body of evidence on the utility of Signatera is growing:<br/><ul type="disc"><br/> 	<li>A 2017 study demonstrated the Signatera RUO method’s ability to detect MRD, measure treatment response, and identify recurrence up to 11 months earlier than the standard of care for early stage non-small-cell lung cancer (NSCLC) with 93 percent sensitivity and zero false positives.4</li><br/> 	<li>Data presented at the&nbsp;European Society for Medical Oncology&nbsp;2018&nbsp;Congress&nbsp;showed successful results from bladder and colorectal cancer studies, including median detection points of MRD that were 3.3 and 7.9 months, respectively, ahead of clinical relapse detection.5,6</li><br/> 	<li>In two studies presented at the 2018 San Antonio Breast Cancer Symposium, Signatera RUO was able to detect MRD up to two years prior to clinical relapse and predict treatment response in a cross-section of breast cancer patients, including those who were HER-2 positive, hormone receptor-positive, and triple negative.7,8</li><br/></ul><br/>Based on numerous studies across multiple cancer types, a positive Signatera RUO result without further treatment has predicted clinical relapse nearly 100 percent of the time.4-8<br/><br/>About&nbsp;Natera<br/><a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=2398906-1&amp;h=2958226392&amp;u=http%3A%2F%2Fwww.natera.com%2F&amp;a=Natera" target="_blank" rel="nofollow noopener">Natera</a>&nbsp;is a global leader in cell-free DNA testing. The mission of the company is to change the management of disease worldwide.&nbsp;Nateraoperates an ISO 13485-certified and CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) in&nbsp;San Carlos, Calif.&nbsp;It offers a host of proprietary genetic testing services to inform physicians who care for pregnant women, researchers in cancer including biopharmaceutical companies, and genetic laboratories through its cloud-based software platform.<br/><br/>Forward-Looking Statements<br/>All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that&nbsp;Natera’s&nbsp;plans, estimates, or expectations will be achieved. These forward-looking statements represent&nbsp;Natera’sexpectations as of the date of this press release, and&nbsp;Natera&nbsp;disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to our or our partners’ efforts to develop and commercialize product offerings,&nbsp;whether standard closing conditions can be met, our partners’ ability to obtain regulatory approvals required to offer our products, our ability to improve, and the effect of any improvements in, our cost of goods sold,&nbsp;our ability to successfully increase demand for and grow revenues for our product offerings, whether the results of clinical studies will support the use of our product offerings, our expectations of the reliability, accuracy and performance of our screening tests, or of the benefits of our screening tests and product offerings to patients, providers and payers, or our expectations regarding our strategic operations. Additional risks and uncertainties are discussed in greater detail in “Risk Factors” in&nbsp;Natera’s&nbsp;recent filings on Forms 10-K and 10-Q and in other filings&nbsp;Natera&nbsp;makes with the&nbsp;SEC&nbsp;from time to time. These documents are available at&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=2398906-1&amp;h=4189340854&amp;u=http%3A%2F%2Fwww.natera.com%2Finvestors&amp;a=www.natera.com%2Finvestors" target="_blank" rel="nofollow noopener">www.natera.com/investors&nbsp;</a>and&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=2398906-1&amp;h=1723542246&amp;u=http%3A%2F%2Fwww.sec.gov%2F&amp;a=www.sec.gov" target="_blank" rel="nofollow noopener">www.sec.gov</a>.<br/><br/>Natera Contacts<br/>Investor Relations:&nbsp;Mike Brophy, CFO,&nbsp;Natera, 650-249-9090<br/>Media:&nbsp;Andrea Sampson, Sullivan &amp; Sampson, 714-374–6174,&nbsp;<a href="mailto:asampson@sullivanpr.com" target="_blank" rel="nofollow noopener">asampson@sullivanpr.com</a><br/><br/>BGI Contacts<br/>Investor Relations:&nbsp;Qian Xu, Secretary Board of Directors, BGI, +86-755-36307888<br/>Media:&nbsp;USA&nbsp;and EMEA,&nbsp;Matt Poulter, Senior Global Marketing Manager,&nbsp;BGI Genomics,&nbsp;<a href="mailto:matt.poulter@bgi.com" target="_blank" rel="nofollow noopener">matt.poulter@bgi.com</a><br/>China&nbsp;and AP,&nbsp;Bicheng Yang, Director,&nbsp;Director Corporate Communications&nbsp;and Public Engagement,&nbsp;BGI Group,&nbsp;<a href="mailto:yangbicheng@genomics.cn" target="_blank" rel="nofollow noopener">yangbicheng@genomics.cn</a><br/><br/>References<br/><ol type="1"><br/> 	<li>BGI internal figures as of 2019.</li><br/> 	<li>Chen W, Zheng R, Baade PD, et al. Cancer statistics in&nbsp;China, 2015.&nbsp;<i>CA Cancer J Clin</i>. 2016;66:115–132.</li><br/> 	<li>China Molecular Diagnostics Market, Volume, by Application [Oncology Testing (Breast Cancer, Colorectal Cancer, Prostate Cancer), Infectious Disease Testing (Virology, HPV), and Genetic Disease Testing (Blood Screening, HLA). 2018, Research and Markets Report, ID: 4607564.</li><br/> 	<li>Abbosh C, Birkbak NJ, Wilson GA, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017;545(7655):446–451.</li><br/> 	<li>Birkenkamp-Demtröder K, Christensen E, Sethi H, et al. Sequencing of Plasma cfDNA from Patients with Locally Advanced Bladder Cancer for Surveillance and Therapeutic Efficacy Monitoring. Poster presented at: European Society for Medical Oncology Annual Congress;&nbsp;October 20, 2018;&nbsp;Munich, Germany. Abstract 86P.</li><br/> 	<li>Reinert T, Henriksen TV, Rasmussen MH, et al. Serial Circulating Tumor DNA Analysis for Detection of Residual Disease, Assessment of Adjuvant Therapy Efficacy and for Early Recurrence Detection in Colorectal Cancer. Poster presented at: European Society for Medical Oncology Annual Congress;&nbsp;October 21, 2018;&nbsp;Munich, Germany. Abstract 456PD.</li><br/> 	<li>Magbanua M, Brown-Swigart L, Hirst G, et al. Personalized serial circulating tumor DNA (ctDNA) analysis in high-risk early stage breast cancer patients to monitor and predict response to neoadjuvant therapy and outcome in the I-SPY 2 TRIAL. Data presented at spotlight session: San Antonio Breast Conference Symposium;&nbsp;December 5, 2018. Abstract 1259.</li><br/> 	<li>Coombes RC, Armstrong A, Ahmed S, Page K, et al. Early detection of residual breast cancer through a robust, scalable and personalized analysis of circulating tumour DNA (ctDNA) antedates overt metastatic recurrence. Poster presented at: San Antonio Breast Conference Symposium;&nbsp;December 7, 2018.&nbsp; Abstract 1266.</li><br/></ol><br/></div></td></tr></tbody></table><br/></div>

Natera and BGI Genomics Announce Partnership in Oncology Testing in China on DNBseq™ Technology Platform

<div data-canvas-width="205.1626666666667"><br/><br/>NGS based Gene Expression analysis has been well documented in the literature and offers distinct benefits over traditional microarray data.<br/><br/><strong>BGISEQ-500 Gene Expression service now offers these benefits at the same price levels as microarray data: a great value!</strong><br/><br/>BGI now offers RNA-Seq(Quantification) Gene Expression Sequencing services based on its own BGISEQ-500 sequencing system, based on cPAS and DNA NanoBall (DNB) technology developed by MGI.<br/><br/></div><br/><em>BGISEQ-500 Gene Expression Sequencing data correlates very well with TaqMan qPCR data and offers nearly unlimited bioinformatics analysis options.</em><br/><div data-canvas-width="138.77599999999998"><span style="color: #ffffff;">XXX&nbsp;</span></div><br/><div data-canvas-width="577.2622222222221"><br/><div data-canvas-width="138.77599999999998">BGISEQ-500 Gene Expression Sequencing includes:</div><br/><ul><br/> 	<li>50bp Single-end sequencing reads</li><br/> 	<li>Standard output 20 Million reads per sample</li><br/> 	<li>Clean filtered sequencing data delivered in standard FASTQ file format</li><br/> 	<li>Customized Gene Expression bioinformatics analysis</li><br/> 	<li>Cloud-based data storage and delivery system</li><br/></ul><br/></div><br/><div data-canvas-width="114.11822222222223"></div><br/><div data-canvas-width="578.4951111111109"></div><br/><div data-canvas-width="138.77599999999998"><br/><br/>Learn More about Gene expression Sequencing performance and how BGI can put your research in overdrive.<br/><br/>&nbsp;<br/><br/></div><br/><h4><span style="color: #9d2431;"><strong>Contact Us Today for a No Obligation Quote</strong></span></h4><br/><div><span style="color: #ffffff;">XXXX</span></div><br/><div data-canvas-width="114.11822222222223"></div><br/><div data-canvas-width="114.11822222222223"></div>

Gene Expression Sequencing at Array Prices!

<strong>BGI Genomics, the industry's lowest-cost provider of WGS, launches two new ambitious plans at J.P. Morgan Healthcare Conference 2018</strong><br/><br/>Jan 11, 2018 | BGI Genomics<br/><br/>Today at the 36th J.P. Morgan Healthcare Conference, Ye Yin, CEO of BGI Genomics, announced that BGI Genomics has successfully sequenced the genome of over 10,000 human samples since it launched the industry's lowest priced Whole Genome Sequencing service at US$600, using the BGISEQ-500, BGI's own sequencing platform.<br/><br/>Ye Yin went on to present two exiting new BGI initiatives: The 2020 Program and the Life Periodic Plan, both of which received strong interest from his audience.<br/><br/><strong>Over 10,000 human WGS samples have been sequenced with the BGISEQ-500 for just US$600 each, the industry's lowest price. </strong><br/><br/>BGI Genomics launched 100G high-quality WGS for the price of US$600 in 2016, still the lowest priced WGS available in the industry. A further 20,000 samples are currently being processed.<br/><br/>Beginning in 1990, the first draft of the human genome took 13 years to complete, involved scientists from 6 countries at a cost of US$3.8 billion. With the rapid development of technology, the cost of sequencing has been driven down consistently.<br/><br/>In 2016, BGI launched the BGISEQ-500 NGS platform. This technology enabled the $600 WGS product that is currently on the market. The BGISEQ-500 delivers high quality and high-throughput sequencing at a low cost, has accelerated the development of genomics, and has set the next benchmark for affordable genomics.<br/><br/><strong>BGI Genomic's launches two ambitious projects: 2020 Program and Life Periodic Plan</strong><br/><br/>At the conference, Ye Yin announced BGI Genomic’s 2020 Program. The ambitious program aims to perform human whole-genome sample sequencing, including sample preparation and data analysis, within 24-hours and below US$300. Ye Yin believes that this will be possible by 2020.<br/><br/>To achieve this, BGI Genomics is collaborating with Intel and Alibaba Cloud to create the most radical innovation in genomics technology with advanced sequencing and computing equipment. BGI Online, BGI's bioinformatics cloud computing platform also plays an important role in the project.<br/><br/>Just last week, BGI Genomics and Edico Genome completed a 100-person WGS project in just 120 minutes using Field Programmable Gate Array (FPGA) technology, representing a significant step towards BGI Genomic's goals.<br/><br/><strong>"Life Periodic Plan will be as significant as the periodic table" according to&nbsp;</strong><strong>Ye Yin, CEO of BGI Genomics</strong><br/><br/>Ye Yin also launched BGI Genomic's Life Periodic Plan at the conference. Its objective is to data mine species through sequencing. This will facilitate the ambitious goal of digitizing all animals and plants on earth, and eventually elucidating the laws of life hidden within the data. The implementation of the Life Periodic Plan could help to protect endangered animals and plants, maintain ecological balance and the diversity of life on earth.<br/><br/><strong>Of the plant and animal species sequenced so far, 70% have been sequenced by BGI Genomics and its collaborators.</strong><br/><br/>The first phase of the Life Periodic Plan is targeted at the existing 27 orders and 157 families of Mammalia. To implement the first phase, BGI Genomics has asked for volunteers from within BGI Genomics and its collaborators to choose individual families to sequence. So far, more than 127 families have been claimed by group leaders. The project will be financed through crowdfunding. Group leaders will direct the genomics analysis, interpretation and knowledge dissemination of the species, to protect their species.<br/><br/>The plant section of the Life Periodic Plan will be launched shortly.

Premium Omics Services at Competitive Prices

Premium Omics Services at Competitive Prices

RNA Sequencing Services

COVID-19 Test Kit

Join Our Upcoming Webinar

News and Events